VISICORT partners met on Friday, November 27, 2020, for an online plenary meeting. All work package updates were presented and plans were drawn up on what needs to occur in the remaining 4 months of the project. Major discussion points focused on the recent biomarker and immunological findings, follow-up data collection for the prospective and clinical variable studies, final reporting requirements, the status of the VISICORT biobank and the clinical trial, our cell product development update, and the progress with the EPIMUNE GmbH collaboration.
Learn more about VISICORT at www.visicort.eu
VISICORT has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602470. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.